Articles tagged with 'Business & Finance' | Bayer

Ready-to-use AgPowered Services from Bayer running on the new Microsoft Azure Data Manager for Agriculture / Readymade capabilities and robust digital infrastructure allow innovators to focus on differentiated value / Companies, farmers and consumers...

Research Triangle Park, N.C.– March 9, 2023 – Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG, today announced that Gustavo Pesquin will become the company’s next Chief Executive Officer (C...

Group sales increase 8.7 percent (Fx & portfolio adj.) to 50.739 billion euros / EBITDA before special items rises 20.9 percent to 13.513 billion euros, largely driven by exceptionally strong performance at Crop Science / Pharmaceuticals increases sa...

LGMD is a Rare Form of Muscular Dystrophy with No Approved Therapies

Closing follows announcement of acquisition on January 18, 2023 / Acquisition bolsters Bayer’s position in digital medical imaging / Blackford will utilize Bayer’s well established “arm’s length” operating model to preserve the company’s entrepreneur...

Leverkusen, February 8, 2023 – The Supervisory Board of Bayer AG has appointed Bill Anderson to become CEO of Bayer, effective June 1, 2023. He will join Bayer as a member of the Board of Management on April 1, 2023. Bill Anderson was elected unanimo...

Oerth’s unique PROTAC® protein degradation technology is expected to be a new, game-changing generation of more sustainable crop protection products / The agreement recommits to the combination of Oerth Bio’s specialized expertise designing PROTAC® d...

Acquisition is part of Bayer’s innovation strategy in radiology / Blackford Analysis provides cutting-edge radiology AI (artificial intelligence) platform technology / Following closing of the acquisition, Blackford Analysis to become part of Bayer’s...

Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells

Strong market uptake of Nubeqa™ and Kerendia™ / Asundexian projected peak sales of more than five billion euros as treatment option for thrombosis and stroke prevention  / High-value late-stage development portfolio  / Positive study outcomes from ce...

Research Triangle Park, N.C. (January 9, 2023) - Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG, announced today that it has signed a multi-year research collaboration and option agreement...

-- Certification expands Viralgen's capacity threefold and positions the company as a world-leading CDMO ---- New facility operates single-use bioreactors from 50 to 2,000 liters and manufactures research, clinical and commercial grade rAAV vectors u...

The Bayer Science Collaboration Explorer makes contract-based scientific collaborations with universities, public research institutions and individuals publicly available in the U.S.  / Aim of the database is to foster public trust in science by show...

Targenomix, a spin-off of the Max Planck Institute for Molecular Plant Physiology, will contribute to Bayer’s Crop Science R&D pipeline by continuing to deliver novel systems biology approaches for innovative crop protection discovery / Targenomix wi...

Chairman of the Board of Management / Chief Financial Officer

Group sales increase by 5.7 percent (Fx & portfolio adj.) to 11.281 billion euros  / EBITDA before special items rises by 17.3 percent to 2.451 billion euros / Crop Science achieves strong sales gains – sales also up at Pharmaceuticals and Consumer H...

California-based NuCicer has developed chickpeas with 75 percent more protein than conventional varieties, unlocking the potential of chickpea protein to become a scalable, affordable foundation for a sustainable plant-based future  / NuCicer’s techn...

Ginkgo Bioworks becomes a multi-year strategic partner with Bayer to develop biological solutions in areas such as nitrogen optimization, carbon sequestration, and next generation crop protection / Open Innovation Sourcing is expected to accelerate B...

Business to continue operations as an independent company called Envu

Succeeds Fei-Fei Li, who stepped down at the end of August

The OCEANIC program will start with two Phase III studies investigating the efficacy and safety of asundexian in prevention of stroke events in patients with atrial fibrillation as well as patients with a non-cardioembolic ischemic stroke or high-ris...

Leverkusen, August 18, 2022 – Bayer supports the humanitarian non-profit organization “Fondation suisse de déminage” (FSD) in their mission to demine land that was contaminated by mines and unexploded devices since the onset of the war in Ukraine. A ...

Leverkusen, August 12, 2022 – Bayer welcomes the dismissal of BASF’s claims by the arbitral tribunal. Bayer provided adequate information on the cost structure of the seeds businesses acquired by BASF in August 2018 and did not breach any contractual...

Group sales increase by 9.6 percent (Fx & portfolio adj.) to 12.819 billion euros / EBITDA before special items rises by 30.0 percent to 3.349 billion euros / Crop Science and Consumer Health achieve strong sales and earnings growth / Pharmaceuticals...

Investment delivers on Bayer’s commitments to sustainability and may help decarbonize agriculture and reduce reliance on nitrogen fertilizer with combined expertise of existing investors, Bunge and Chevron / Growers to gain new revenue streams throug...

Supports ongoing transformation of Bayer’s Pharma business to focus on key areas of future medical innovation / Transaction value of up to 500 million Euro / Closing expected by end of 2022

Establishment of new precision molecular oncology research center to drive development of novel targeted cancer therapies for patients with unmet medical need / Strategic investment of $140M USD to expand presence in leading center of biotech innovat...

Investment of approximately 275 million euros in the world’s first learning pharmaceutical production facility / 70 percent lower CO2 emissions than conventional plants

Group sales grow by 14.3 percent (Fx & portfolio adj.) to 14.639 billion euros / EBITDA before special items increases by 27.5 percent to 5.251 billion euros / Substantial sales and earnings growth at Crop Science and Consumer Health / Sales up sligh...

Chairman of the Board of Management